The company has developed several proprietary immuno-oncology therapeutic platforms, including TriTETM, CCNKTM, and CCMφTM. The pipeline antibodies developed based on these platforms could stimulate or modulate immune cells to fight against cancer.
CytoCares is a pioneer in utilizing of “Two-Signal” system of T cell activation in the multi-specific antibody design and has expanded its expertise from hematologic malignancies to solid tumor.
Trispecific T-cell Engager (TriTE) offering full activation signal to T cell through co-engagement of TCR/CD3 and co-stimulatory receptor
NK activation receptor agonists or inhibitory receptor antagonists for effective tumor killing
Marcrophage revitalize agents to enhance innate as well as adaptive immunity for cancer treatment
2024年8月11日，惠和生物申報的1類新藥CC312凍干粉針劑獲批臨床，適應(yīng)癥為自身免疫疾病系統(tǒng)性紅斑狼瘡（SLE）。
2024年6月3日，惠和生物在自免疾病領(lǐng)域的IND申請已正式獲得國家藥品監(jiān)督管理局藥品審評中心（CDE）受理！
2024年5月24日下午，惠和生物組織的閉門學(xué)術(shù)研討沙龍成功舉辦，與會嘉賓們圍繞著“細(xì)胞免疫、新藥與臨床轉(zhuǎn)化”的主題進(jìn)行分享、討論和交流。
